The osteoporosis medications teriparatide, romosozumab, raloxifene and denosumab all confer significant benefits for reducing vertebral and hip fractures and inducing changes in bone mineral density at the femoral neck as compared with placebo, according to the results of a network meta-analysis.
In patients with active psoriatic arthritis (PsA), treatment with secukinumab at 300 and 150 mg with or without loading regimen inhibits radiographic progression, the rates of which remaining low over 52 weeks of treatment, while showing consistent clinical efficacy and a favourable safety profile, according to the 52-week data from phase III FUTURE 5 trial.
The Janus kinase inhibitor tofacitinib remained effective and safe even after discontinuing the csDMARD* methotrexate in patients with moderate-to-severe rheumatoid arthritis (RA) who achieved low disease activity (LDA) with a combination of the two drugs, the ORAL Shift** trial suggests, highlighting the feasibility of methotrexate withdrawal in this setting.
The addition of the monoclonal immunoglobulin G1 antibody bimekizumab to the anti-TNF* certolizumab pegol (CZP) led to a reduction in disease activity in rheumatoid arthritis (RA) patients with insufficient response to CZP, a study shows.
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The efficacy and safety of the biosimilar IBI303 mirrored that of the monoclonal anti-TNFα* antibody adalimumab, thus providing a new and affordable treatment alternative for individuals with ankylosing spondylitis, according to a Chinese study.
Implementation of the collaborative care in a rheumatoid arthritis (RA) clinic has led to improvements in nonbiologic disease-modifying antirheumatic drugs (nb-DMARDs) optimization, adherence to safety recommendations on nb-DMARD monitoring and detection of adverse drug events in RA patients, according to a Singapore study.
New drug applications approved by US FDA as of 16 - 31 August 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Use of the Janus kinase (JAK) inhibitor upadacitinib in the treatment of rheumatoid arthritis (RA) yields significant improvements in signs, symptoms and physical function, in addition to inhibiting radiographic progression as compared with placebo, according to the results of the phase III SELECT-COMPARE trial.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.